Colleen Pawliuk1, Briana Chau1, S Rod Rassekh2, Terri McKellar3, Harold Hal Siden1,2. 1. Department of Paediatrics, BC Children's Hospital Research Institute, Vancouver, British Columbia. 2. Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia. 3. Physiotherapy Association of British Columbia, Vancouver, British Columbia.
Abstract
INTRODUCTION: The use of medicinal cannabis in the paediatric age group is increasing despite the lack of evidence for its efficacy or safety. OBJECTIVE: To map the available evidence on the efficacy and safety of medicinal cannabis in children and adolescents. METHODS: We conducted a scoping review and searched six electronic databases and grey literature. A study was eligible for inclusion when it investigated the efficacy or safety of medicinal cannabis for any condition, more than half of the participants were 0 to 18 years old, and had any study design except single case reports. RESULTS: We included 36 studies in our final analysis, 32 of which investigated the efficacy or safety of cannabis in treatment-resistant epilepsy. The remaining 4 studies examined patients with cancer, dysautonomia, Epidermolysis Bullosa, and motor disorders. CONCLUSIONS: There is a lack of evidence on the efficacy and safety of medicinal cannabis in most paediatric conditions.
INTRODUCTION: The use of medicinal cannabis in the paediatric age group is increasing despite the lack of evidence for its efficacy or safety. OBJECTIVE: To map the available evidence on the efficacy and safety of medicinal cannabis in children and adolescents. METHODS: We conducted a scoping review and searched six electronic databases and grey literature. A study was eligible for inclusion when it investigated the efficacy or safety of medicinal cannabis for any condition, more than half of the participants were 0 to 18 years old, and had any study design except single case reports. RESULTS: We included 36 studies in our final analysis, 32 of which investigated the efficacy or safety of cannabis in treatment-resistant epilepsy. The remaining 4 studies examined patients with cancer, dysautonomia, Epidermolysis Bullosa, and motor disorders. CONCLUSIONS: There is a lack of evidence on the efficacy and safety of medicinal cannabis in most paediatric conditions.
Authors: Shaun A Hussain; Raymond Zhou; Catherine Jacobson; Julius Weng; Emily Cheng; Johnson Lay; Phoebe Hung; Jason T Lerner; Raman Sankar Journal: Epilepsy Behav Date: 2015-04-29 Impact factor: 2.937
Authors: Jerzy P Szaflarski; Elizabeth Martina Bebin; Gary Cutter; Jennifer DeWolfe; Leon S Dure; Tyler E Gaston; Pongkiat Kankirawatana; Yuliang Liu; Rani Singh; David G Standaert; Ashley E Thomas; Lawrence W Ver Hoef Journal: Epilepsy Behav Date: 2018-08-09 Impact factor: 2.937
Authors: Jerzy P Szaflarski; Elizabeth Martina Bebin; Anne M Comi; Anup D Patel; Charuta Joshi; Daniel Checketts; Jules C Beal; Linda C Laux; Lisa M De Boer; Matthew H Wong; Merrick Lopez; Orrin Devinsky; Paul D Lyons; Pilar Pichon Zentil; Robert Wechsler Journal: Epilepsia Date: 2018-07-12 Impact factor: 5.864
Authors: Richard J Huntsman; Lauren E Kelly; Jane Alcorn; Juan Pablo Appendino; Richard E Bélanger; Bruce Crooks; Yaron Finkelstein; Andrea Gilpin; Evan Lewis; Catherine Litalien; Julia Jacobs; Charlotte Moore-Hepburn; Timothy Oberlander; S Rod Rassekh; Alexander E Repetski; Michael J Rieder; Alan Shackelford; Hal Siden; Michael Szafron; Geert W 't Jong; Régis Vaillancourt Journal: CMAJ Date: 2021-10-18 Impact factor: 8.262
Authors: Richard J Huntsman; Lauren E Kelly; Jane Alcorn; Juan Pablo Appendino; Richard E Bélanger; Bruce Crooks; Yaron Finkelstein; Andrea Gilpin; Evan Lewis; Catherine Litalien; Julia Jacobs; Charlotte Moore-Hepburn; Timothy Oberlander; S Rod Rassekh; Alexander E Repetski; Michael J Rieder; Alan Shackelford; Hal Siden; Michael Szafron; Geert W 't Jong; Régis Vaillancourt Journal: CMAJ Date: 2021-12-06 Impact factor: 8.262